Bristol Myers Squibb
Lawrenceville, NJ, United States
Alaric Dyckman received a B.S. degree in Chemistry from California State University, Chico, and a Ph.D. in Organic Chemistry from Stanford University, studying in the lab of Prof. Paul Wender. In 2000, he joined Bristol Myers Squibb as a medicinal chemist in the Immunoscience therapeutic area, initially working on a range of kinase targets, including TYK2, BTK and p38alpha, for which development compounds were identified. In addition, he has led programs for the treatment of autoimmune disorders. As the Chemistry lead for the S1P1 Agonist program, he oversaw the identification and advancement of several clinical development candidates, including BMS-986166 which entered clinical trials for Atopic Dermatitis. He initiated the Toll-like Receptor targeting programs at BMS, and drove the identification of multiple development compounds, including afimetoran, a potent and selective TLR7/8 dual antagonist under clinical evaluation for Systemic and Cutaneous Lupus Erythematosus.
Monday, November 13, 2023
9:00 AM – 11:00 AM PT
Disclosure information not submitted.
